VolitionRX (NYSEAMERICAN:VNRX) Announces Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) announced its earnings results on Tuesday. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05), FiscalAI reports. The company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.71 million.

VolitionRX Stock Performance

Shares of VolitionRX stock traded up $0.01 during trading on Tuesday, hitting $0.20. 6,929,788 shares of the company’s stock were exchanged, compared to its average volume of 28,654,266. The stock has a market capitalization of $27.39 million, a price-to-earnings ratio of -0.88 and a beta of 1.33. The business has a 50-day simple moving average of $0.22 and a 200-day simple moving average of $0.34. VolitionRX has a 52-week low of $0.17 and a 52-week high of $0.94.

Institutional Investors Weigh In On VolitionRX

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC boosted its stake in shares of VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 85,816 shares in the last quarter. Citadel Advisors LLC raised its holdings in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the period. Squarepoint Ops LLC acquired a new position in VolitionRX in the 4th quarter worth about $34,000. Finally, Jane Street Group LLC purchased a new position in VolitionRX during the fourth quarter worth approximately $28,000. Hedge funds and other institutional investors own 8.09% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Maxim Group cut VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reiterated a “buy” rating and issued a $3.00 target price on shares of VolitionRX in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $2.50.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.